HC Wainwright Has Pessimistic Outlook of SLN FY2024 Earnings

Silence Therapeutics plc (NASDAQ:SLN) – Equities research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for Silence Therapeutics in a research note issued on Wednesday, January 29th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.73) for the year, down from their previous forecast of ($1.60). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($0.41) EPS.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley reissued an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $54.75.

Silence Therapeutics Stock Down 5.1 %

SLN stock opened at $5.06 on Monday. The business has a fifty day moving average of $6.56 and a two-hundred day moving average of $13.63. The stock has a market cap of $151.45 million, a price-to-earnings ratio of -3.22 and a beta of 1.05. Silence Therapeutics has a 52-week low of $4.82 and a 52-week high of $27.72.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SLN. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics during the 4th quarter worth about $69,000. FNY Investment Advisers LLC purchased a new stake in Silence Therapeutics during the 4th quarter worth about $120,000. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after buying an additional 5,233 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its holdings in Silence Therapeutics by 22.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after buying an additional 3,923 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in Silence Therapeutics by 219.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after buying an additional 321,300 shares during the last quarter. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.